Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy
NCT04479514Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2020
- Primary completion
- Jan 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Rate of Cutaneous Reaction at 12 weeks. Started Oct 2020; status: completed.
Beyond the preview
Go deeper on NCT04479514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04479514.